Drug Profile
Rheumatoid arthritis therapeutic biosimilar - Zydus Cadila
Alternative Names: Prod 2Latest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for research development in Rheumatoid-arthritis in India (Parenteral)
- 28 Feb 2014 Early research in Rheumatoid arthritis in India (Parenteral)